Cydan is focused on accelerating the development of meaningful therapies for people living with rare genetic diseases. Our goal is to launch successful, independent companies that accelerate new therapies through clinical development to commercialization. Cydan is not a venture capital investor or the diligence arm of any VC firm. Our collaborative model results in new companies launched with the backing of Cydan and a clear clinical development and regulatory path forward for an orphan drug candidate. Cydan NewCos are started with an initial Series A round of funding, an established management team, a compelling corporate story and clear path to human clinical proof of concept.

Cydan was launched in 2013 with $26 million in financing led by New Enterprise Associates (NEA), Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Real Estate Equities, Inc. Our Cydan NewCos have access to the same investor syndicate.

Vtesse, our first new company, was launched in 2015.

Imara, our second new spinout, focused on sickle cell disease, was launched in 2016.

Tiburio, our third new spinout, advancing novel treatments for rare neuroendocrine tumors and rare endocrine diseases, was launched in 2019.